About Nykode Therapeutics ASA

Company Description

Nykode Therapeutics is a leading clinical-stage biopharmaceutical company. With our intelligent modular platform and tailored hyper-targeting, we’re unlocking unlimited possibilities for the future of medicine.

With our unique and innovative modular vaccine technology, we’re specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting immune responses.

Year founded

2007

Served area

Worldwide

Headquarters

Gaustadalléen 21, 0349 Oslo – Norway

Shareholder information

Shares outstanding

294,694,309

IPO

Oct. 7, 2020

Stock exchange(s)

Euronext Oslo

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.